Paper41111360
Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
Barazzoni R and 10 others. Diabetes Obes Metab, 2026. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity. Papers, record 41111360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41111360
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Obesity | Major topic |
| Bariatric Surgery | Major topic |
| Anti-Obesity Agents | Major topic |
| Overweight | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Practice Guidelines as Topic | |
| Italy | |
| Treatment Outcome | |
| Weight Loss |
Source PubMed
References168
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26369473 | Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. | Lancet | 2015 | https://conductscience.org/library/papers/26369473 | PubMed |
| 2 | 31931977 | Adjustable gastric band surgery or medical management in patients with type 2 diabetes and obesity: three-year results of a randomized trial. | Surg Obes Relat Dis | 2019 | https://conductscience.org/library/papers/31931977 | PubMed |
| 3 | 9886891 | Treatment with orlistat reduces cardiovascular risk in obese patients. | J Hypertens | 1998 | https://conductscience.org/library/papers/9886891 | PubMed |
| 4 | 23180572 | Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty. | Br J Surg | 2013 | https://conductscience.org/library/papers/23180572 | PubMed |
| 5 | 32976702 | Simultaneous robotic kidney transplantation and bariatric surgery for morbidly obese patients with end-stage renal failure. | Am J Transplant | 2021 | https://conductscience.org/library/papers/32976702 | PubMed |
| 6 | 36717470 | Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Treating Obesity in Patients > 65 Years Old: 3-Year Outcomes of a Randomized Trial. | J Gastrointest Surg | 2023 | https://conductscience.org/library/papers/36717470 | PubMed |
| 7 | 18376181 | Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. | Ann Surg | 2008 | https://conductscience.org/library/papers/18376181 | PubMed |
| 8 | 26198306 | Long-term effects of laparoscopic sleeve gastrectomy versus roux-en-Y gastric bypass for the treatment of Chinese type 2 diabetes mellitus patients with body mass index 28-35 kg/m(2). | BMC Surg | 2015 | https://conductscience.org/library/papers/26198306 | PubMed |
| 9 | 34406598 | Laparoscopic One Anastomosis Gastric Bypass Versus Laparoscopic Roux-en-Y Gastric Bypass Effects on Pre-existing Mild-to-Moderate Gastroesophageal Reflux Disease in Patients with Obesity: a Randomized Controlled Study. | Obes Surg | 2021 | https://conductscience.org/library/papers/34406598 | PubMed |
| 10 | 39612579 | International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). | Br J Surg | 2024 | https://conductscience.org/library/papers/39612579 | PubMed |
| 11 | 35131037 | Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. | Lancet Diabetes Endocrinol | 2022 | https://conductscience.org/library/papers/35131037 | PubMed |
| 12 | 37385275 | Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37385275 | PubMed |
| 13 | 29043548 | Comparison of Short-Term Effectiveness and Postoperative Complications: Laparoscopic Gastric Plication vs Laparoscopic Sleeve Gastrectomy. | Obes Surg | 2018 | https://conductscience.org/library/papers/29043548 | PubMed |
| 14 | 12087008 | Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. | Diabetes Care | 2002 | https://conductscience.org/library/papers/12087008 | PubMed |
| 15 | 21339423 | Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. | Arch Surg | 2011 | https://conductscience.org/library/papers/21339423 | PubMed |
| 16 | 27353417 | GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. | BMJ | 2016 | https://conductscience.org/library/papers/27353417 | PubMed |
| 17 | 29340679 | Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. | JAMA | 2018 | https://conductscience.org/library/papers/29340679 | PubMed |
| 18 | 39476339 | Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39476339 | PubMed |
| 19 | 17192328 | Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. | Diabetes Care | 2007 | https://conductscience.org/library/papers/17192328 | PubMed |
| 20 | 9702435 | Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. | Diabetes Care | 1998 | https://conductscience.org/library/papers/9702435 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42426361 | Efficacy and Safety of Anti-Obesity Medications for Weight Loss Maintenance in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42426361 | PubMed |
| 42387279 | Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42387279 | PubMed |
| 41954678 | Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives. | Rev Endocr Metab Disord | 2026 | https://conductscience.org/library/papers/41954678 | PubMed |
| 41533187 | Italian clinical practice GRADE-based guidelines on the diagnosis and treatment of overweight and obesity, endorsed by the Italian National Institute of Health. | Eat Weight Disord | 2026 | https://conductscience.org/library/papers/41533187 | PubMed |
| 41111360 | Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/41111360 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41111360
GET https://conductscience.org/api/papers/v1/41111360/references?page=2